Association between Genetic Polymorphism of SCN1A, GABRA1 and ABCB1 and Drug Responsiveness in Vietnamese Epileptic

Hai Xuan Tang1, Muoi Dang Ho1, Nhung Phuong Vu2

  • 1Nghe An Obstetrics and Pediatrics Hospital, 19 Ton That Tung, Vinh 460000, Nghe An, Vietnam.

PubMed

Insights

Genetic variations in the SCN1A gene are linked to drug-resistant epilepsy in Vietnamese children. Specific SCN1A polymorphisms increase the risk of refractory epilepsy, impacting treatment outcomes.

Area of Science:

  • Genetics
  • Neurology
  • Pharmacogenomics

Background:

  • Drug-resistant epilepsy (DRE) presents a significant challenge in managing epilepsy, affecting patient care and treatment success.
  • Genetic factors, including variants in genes encoding drug targets and transporters, may contribute to DRE.
  • Understanding genetic predispositions is crucial for improving epilepsy treatment strategies.

Purpose of the Study:

  • To investigate the association between polymorphisms in SCN1A, GABRA1, and ABCB1 genes and drug response in Vietnamese children with epilepsy.
  • To identify specific genetic variants that may serve as risk factors for drug-resistant epilepsy.

Main Methods:

  • A cohort of 213 Vietnamese children with epilepsy (101 drug-responsive, 112 drug-resistant) was analyzed.
  • Sanger sequencing was used to identify six single nucleotide polymorphisms (SNPs) in SCN1A, GABRA1, and ABCB1 genes.
  • Statistical analyses (Chi-squared test, Fisher's exact test) were employed to correlate SNP genotypes with drug response status.

Main Results:

  • Two out of six investigated SNPs showed a significant association with drug response.
  • The heterozygous genotype of SCN1A rs2298771 (AG) was more frequent in drug-resistant epilepsy patients, indicating a risk factor.
  • The heterozygous genotype of SCN1A rs3812718 (CT) was less frequent in drug-resistant patients compared to drug-responsive patients.

Conclusions:

  • This study highlights a significant association between SCN1A genetic polymorphisms and an increased risk of drug-resistant epilepsy in Vietnamese children.
  • These findings support the role of SCN1A gene variants in the pathogenesis of childhood drug-resistant epilepsy.
  • Identifying these genetic markers could aid in predicting treatment outcomes and developing personalized epilepsy management strategies.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
287
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
388
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
176
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
325
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
518
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
188